Korean Biomedical Review is reporting that Alteogen will transfer technology related to its ALT-L2, a biosimilar of Herceptin, to Qilu Pharmaceutical of China.

According to the article, Alteogen and Qilu will “jointly complete the development of” the product and “cooperate for its approval, production and marketing in China”.

The article states that Alteogen will conduct phase 3 clinical trials of ALT-L2, which was the subject of a phase 1 clinical trial in Canada and was exempted from a phase 2 clinical trial, and that Alteogen will receive royalties based on the developmental stages and marketing of ALT-L2.

The article did not report any additional terms of the agreement.